iteos news - Search News

GSK, iTeos

Lung cancer drug from iTeos, GSK shows response, boosting TIGIT as a viable target

A targeted immunotherapy being developed by iTeos Therapeutics and GSK, it was reported at #ESMO, delivered promising response rates in patients with a type of lung cancer.

YAHOO!Finance · 5d

TIGIT drug from iTeos shrinks lung tumors in trial

Results presented at ESMO showed tumor response rates that matched the bar set by analysts for success. But they may not yet be enough to dispel doubts around TIGIT as a target.

MarketWatch · 3d

ITeos Therapeutics Shares Rise on Positive Data From Lung Cancer Study

Shares in iTeos Therapeutics rose after the company reported positive data from a mid-stage study exploring the combination of belrestotug and dostarlimab in the first-line treatment of lung cancer. Shares were up 22% in premarket trading at $20.40. The stock is up more than 52% this year.

Bloomberg L.P. · 5d

GSK, iTeos Lung Cancer Data Set to Reignite Hope for Drug Class

Early data from GSK Plc and iTeos Therapeutics’ mid-stage trial of a lung cancer medicine looks set to renew cautious optimism around a class of immunotherapy drugs that has suffered a series of setbacks.

Seeking Alpha · 5d

GSK, iTeos lung cancer therapy outperforms Jemperli in mid-stage trial

Teos (ITOS) stock is in focus as experimental cancer doublet therapy, developed with GSK, outperformed Jemperliin a mid-stage trial for lung cancer. Read more here.

3don MSN

iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were mixed this morning, with the Dow futures gaining around 100 points on Monday. Shares of iTeos ...

FierceBiotech5d

UPDATED: iTeos-GSK's TIGIT combo shows 30% more tumor shrinkage than Jemperli, but safety signals scare investors

After announcing a phase 3 launch based on positive midstage results, iTeos and GSK are finally sharing the highlights from ...

Investor's Business Daily on MSN3d

Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths

Biotech stocks Nuvalent and Iteos diverged Monday on updates for their lung cancer treatments at the ESMO meeting in Madrid.

GSK, iTeos Score Phase II Win for Jemperli-TIGIT Combo in NSCLC

High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light ...

3d

Promising Efficacy and Market Potential: iTeos Therapeutics’ Combination Therapy Exceeds Phase 2 Expectations

Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on iTeos Therapeutics (ITOS – Research Report). The ...

ESMO: GSK, iTeos bring some optimism back to TIGIT

The results of the GALAXIES Lung-02 study reported at the ESMO congress in Barcelona showed that the drug – added to GSK's PD ...

3d

ESMO 2024: TIGIT race tightens with first look at GSK/iTeos’s TIGIT in NSCLC

The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC ...

5d

Buy Rating Affirmed for iTeos Therapeutics Amid Promising Lung-201 Study Outcomes

Eva Fortea Verdejo, an analyst from Wells Fargo, maintained the Buy rating on iTeos Therapeutics (ITOS – Research Report). The associated ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results